Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology

被引:59
作者
Huijgens, PC
Simoons-Smit, AM
van Loenen, AC
Prooy, E
van Tinteren, H
Ossenkoppele, GJ
Jonkhoff, AR
机构
[1] Vrije Univ Amsterdam, Univ Hosp, Dept Haematol, NL-1081 HV Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Univ Hosp, Dept Clin Microbiol & Infect Control, NL-1081 HV Amsterdam, Netherlands
[3] Vrije Univ Amsterdam, Univ Hosp, Dept Pharm, NL-1081 HV Amsterdam, Netherlands
[4] Pfizer BV, Ijssel, Netherlands
[5] Ctr Comprehens Canc, Amsterdam, Netherlands
关键词
fungal infection; haematological malignancy; imidazoles;
D O I
10.1136/jcp.52.5.376
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Aims-To compare the efficacy of and tolerance to oral fluconazole and intraconazole in preventing fungal infection in neutropenic patients with haematological malignancies. Patients-213 consecutive, afebrile adult patients treated with or without autologous stem cell transplantation for haematological malignancies. Methods-A randomised, double blind, single centre study. Patients were randomly assigned to receive fluconazole 50 mg or itraconazole 100 mg, both twice daily in identical capsules. An intention to treat analysis was performed on 202 patients, 101 in each group. Results-Microbiologically documented systemic fungal infections occurred in four patients in each group. Clinical fungal infection was thought to be present in seven recipients of fluconazole and four of itraconazole. In all 202 patients, 29 proceeded to intravenous amphotericin (amphotericin B), 16 in the fluconazole group and 13 in the itraconazole group. Superficial fungal infection was seen only in three non-compliant patients in the fluconazole group. All these infections were oral. No major differences were noted in the isolates of fungi in mouth washes and fecal samples. Overall mortality was 8.9% (18 deaths; seven in the fluconazole group, 11 in the itraconazole group), Mortality from microbiologically and clinically documented fungal infection was 4.5% (nine deaths; three in the fluconazole group, six in the itraconazole group). Median time to suspected or proven fungal infection was 16 days in both groups. None of these comparisons reached statistical significance (p < 0.05). No major clinical toxicity was noted and compliance was excellent. Conclusions-In neutropenic patients treated for haematological malignancies with or without autologous stem cell transplantation, fluconazole and itraconazole in low doses result in a similar low frequency of fungal disease. Fluconazole may be the preferable drug because of the smaller number of capsules and lack of need for timing relative to meals.
引用
收藏
页码:376 / 380
页数:5
相关论文
共 31 条
[1]  
ALANGADEN G, 1994, BONE MARROW TRANSPL, V14, P919
[2]   ANTIFUNGAL PROPHYLAXIS WITH ITRACONAZOLE IN PROLONGED NEUTROPENIA - CORRELATION WITH PLASMA-LEVELS [J].
BOOGAERTS, MA ;
VERHOEF, GE ;
ZACHEE, P ;
DEMUYNCK, H ;
VERBIST, L ;
DEBEULE, K .
MYCOSES, 1989, 32 :103-108
[3]   Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: Effect of augmented gram-positive activity on infectious morbidity [J].
Bow, EJ ;
Mandell, LA ;
Louie, TJ ;
Feld, R ;
Palmer, M ;
Zee, B ;
Pater, J .
ANNALS OF INTERNAL MEDICINE, 1996, 125 (03) :183-+
[4]  
BUCHANAN AG, 1985, CLIN INVEST MED, V8, P139
[5]   A meta-analysis of clinical studies of imipenem-cilastatin for empirically treating febrile neutropenic patients [J].
Deaney, NB ;
Tate, H .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 37 (05) :975-986
[6]   ANTIFUNGAL PROPHYLAXIS DURING NEUTROPENIA OR ALLOGENEIC BONE-MARROW TRANSPLANTATION - WHAT IS THE STATE-OF-THE-ART [J].
DENNING, DW ;
DONNELLY, JP ;
HELLREIGEL, KP ;
ITO, J ;
MARTINO, P ;
VANTWOUT, JW .
CHEMOTHERAPY, 1992, 38 :43-49
[7]   A CONTROLLED TRIAL OF FLUCONAZOLE TO PREVENT FUNGAL-INFECTIONS IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION [J].
GOODMAN, JL ;
WINSTON, DJ ;
GREENFIELD, RA ;
CHANDRASEKAR, PH ;
FOX, B ;
KAIZER, H ;
SHADDUCK, RK ;
SHEA, TC ;
STIFF, P ;
FRIEDMAN, DJ ;
POWDERLY, WG ;
SILBER, JL ;
HOROWITZ, H ;
LICHTIN, A ;
WOLFF, SN ;
MANGAN, KF ;
SILVER, SM ;
WEISDORF, D ;
HO, WG ;
GILBERT, G ;
BUELL, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (13) :845-851
[8]   Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia [J].
Gotzsche, PC ;
Johansen, HK .
BMJ-BRITISH MEDICAL JOURNAL, 1997, 314 (7089) :1238-1244
[9]   THE PROPHYLACTIC USE OF FLUCONAZOLE 50 VS 100 MG DAILY IN HEMATOLOGICAL MALIGNANCIES [J].
HUIJGENS, PC ;
VANLOENEN, AC ;
SIMOONSSMIT, AM ;
PROOY, E ;
OSSENKOPPELE, GJ .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (06) :926-927
[10]  
HUIJGENS PC, 1991, EUR J HAEMATOL, V46, P42